论文部分内容阅读
目的 检测胆管良、恶性疾病患者的血清IL 6水平 ,探讨胆管癌和胆管良性疾病的鉴别以及与肿瘤负荷的相关性。方法 采用ELISA双抗体夹心法测定 30例胆管良性疾病患者 ,2 5例胆管癌患者和 2 0例健康者的血清IL 6水平 ,并对胆管癌患者手术前后血清IL 6的水平变化进行观察。结果 2 5例胆管癌患者血清IL 6水平明显高于胆管良性疾病及健康者 (P <0 0 5 ) ,胆管癌手术后血清IL 6水平明显低于手术前 ,差异有显著意义 (P <0 0 5 )。结论 胆管癌患者血清IL 6水平明显增高 ,检测血清IL 6可做为诊断胆管癌的重要指标。
Objective To detect serum IL-6 levels in patients with benign and malignant bile duct diseases and to investigate the differentiation of bile duct cancer and benign bile duct diseases and their correlation with tumor burden. Methods Serum IL-6 levels in 30 patients with benign biliary disease, 25 patients with cholangiocarcinoma and 20 healthy subjects were determined by ELISA double antibody sandwich method. Serum IL-6 levels in patients with cholangiocarcinoma before and after surgery were observed. Results The serum IL 6 levels in 25 patients with cholangiocarcinoma were significantly higher than those with benign bile duct disease and healthy persons (P < 0.05). The serum IL 6 levels after cholangiocarcinoma surgery were significantly lower than before surgery. The difference was significant (P <0). 0 5 ). Conclusion Serum IL-6 levels in patients with cholangiocarcinoma are significantly higher. Detection of serum IL 6 may be an important indicator for the diagnosis of cholangiocarcinoma.